Tutti gli studi
ReclutamentoPhase IIIInterventistico

Study evaluating the efficacy of icotrokinra in ulcerative colitis

Researchers are looking for adults and teenagers (aged 12 and over) with moderate to severe ulcerative colitis (UC) to take part in a study testing a new medicine called icotrokinra. UC is a long-term condition where the large bowel becomes inflamed and develops small sores. While there are treatments, not everyone finds them effective or easy to tolerate. Icotrokinra aims to reduce inflammation by blocking a specific protein in the body. The study will compare icotrokinra to a dummy medicine (placebo) to see if it can help calm UC symptoms and keep them under control. It will also check for any side effects.

A colpo d'occhio

Stato
Reclutamento
Fase
Phase III
Sponsor
Janssen-Cilag International N.V.
Obiettivo di iscrizione
882
Inizio
01 Ott 2025
Completamento stimato
08 Dec 2026

Di cosa tratta questo studio?

Ulcerative colitis (UC) is a long-term condition that affects your large bowel (colon). It causes the lining of your bowel to become inflamed and develop tiny open sores. This can lead to symptoms like tummy pain, diarrhoea, and blood in your poo. Even though there are treatments available, they don't work for everyone, or some people find the side effects too difficult to manage. This means there's a need for new and better medicines for UC.

This study is looking at a new medicine called icotrokinra. Our bodies have proteins that can cause inflammation, and one of these is called interleukin-23 (IL-23). Icotrokinra works by stopping IL-23 from connecting to its partner protein, which helps to reduce the inflammation that causes many of the uncomfortable UC symptoms. The main goal of this study is to find out how well icotrokinra can help settle down UC symptoms (this is called 'inducing remission') and then keep the disease under control (this is called 'maintaining remission').

We'll be studying both adults and teenagers (aged 12 and over) who have UC that is currently quite active, meaning they are experiencing noticeable symptoms. The study will compare icotrokinra to a dummy medicine (placebo) in adults to see if it's more effective. For teenagers, the study will focus on how well icotrokinra works overall. We'll also be carefully checking for any side effects of the new medicine throughout the study.

Punti chiave

  • New medicine (icotrokinra) for moderate to severe ulcerative colitis is being tested.
  • Aimed at reducing inflammation and controlling symptoms.
  • Open to adults and teenagers (12 years and older).
  • Compares icotrokinra to a dummy medicine in adults; teenagers get icotrokinra.
  • Total study duration is about 5 years, with regular check-ups.
  • Participation costs are covered, and travel expenses reimbursed.

Chi può essere idoneo?

You might be able to join this study if you are an adult aged 18 or older, or a teenager aged 12 to under 18. You need to have been diagnosed with ulcerative colitis at least 12 weeks before the study starts, and a doctor will have confirmed this using an examination of your bowel and tissue samples.

Your ulcerative colitis needs to be classed as moderate to severe and currently active when you join the study. This will be checked by a special score based on a camera examination of your bowel. You will also need to have had a full colonoscopy (bowel examination) to check for any abnormal cells in the last year, especially if you've had UC for a long time or it affects a large part of your bowel.

There are also some reasons why you might not be able to join. For example, if you have severe complications of UC like a sudden, serious flare-up or a very swollen bowel, or if you've had certain bowel surgeries recently, you won't be able to take part. Also, if you have a stoma (a surgically created opening in your tummy) or a history of certain abnormal cells in your bowel, you won't be eligible.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Are you 12 years old or older?
  2. Do you have a confirmed diagnosis of ulcerative colitis?
  3. Is your ulcerative colitis currently active (moderate to severe symptoms)?
  4. Have you had a recent bowel examination (colonoscopy or sigmoidoscopy)?
  5. Do you not have certain severe complications of UC like a very swollen bowel?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to take part, the study will involve several stages over about five years. First, there's a 'Screening' period of up to 6 weeks where we check if you're suitable for the study. After that, for adults, there's a 12-week 'Induction' phase where you'll receive the study medicine (or a dummy medicine) daily. This is followed by a 40-week 'Maintenance' phase, still with daily medicine. For teenagers, there's a 52-week combined 'Induction and Maintenance' phase, with daily medicine.

Both adults and teenagers can then continue into a 'Long-term extension' phase for up to four years, still taking daily medicine. After your last dose of study medicine, there's a four-week 'Safety follow-up' period. Throughout the study, you'll have regular check-ups, which include physical examinations, blood tests, and heart tracings (ECGs). We'll also monitor for any side effects, including specific checks for tuberculosis and your mood. The study team will cover the cost of the study medicine and tests, and you'll receive some money back for travel or parking expenses.

Rischi e benefici potenziali

It's important to know that while taking part in this study may offer some potential benefits, nothing is guaranteed. We hope that icotrokinra may improve your UC symptoms, but because it's a new medicine being investigated, we can't be certain. Some people find that participating in studies can lead to benefits from the regular medical check-ups and monitoring you'll receive. Also, your participation could help us learn valuable information that might help other people with UC in the future. However, there are potential risks. You might experience side effects from the study medicine or procedures, which can range from mild to severe, and in very rare cases, could even be life-threatening. These could include allergic reactions, your body reacting to the drug, or infections. There are also risks linked to procedures like camera examinations of your bowel, such as bleeding or discomfort. Not all possible side effects are known yet, but the study team will tell you immediately if any new important information comes to light. You will always have the right to withdraw from the study at any time.

Luoghi (9)

  • Fairfield General Hospital
    Non verificato
    Bury, England
  • St George's University Hospital NHS Foundation Trust
    Non verificato
    London, England
  • Ospedale Addenbrooke
    Non verificato
    Cambridge, England
  • Kings College Hospital
    Non verificato
    London, England
  • Whiston Hospital
    Non verificato
    Prescot, England
  • Ospedale Universitario Whipps Cross
    Non verificato
    London, England
  • Ospedale Stepping Hill
    Non verificato
    Stockport, England
  • Sheffield Children's Hospital
    Non verificato
    Sheffield, England
  • Ospedale Reale per Bambini e Giovani
    Non verificato
    Lothian, Scotland

Domande comuni

What is ulcerative colitis?

It's a long-lasting condition where the lining of your large bowel (colon) gets inflamed and develops small sores.

What is icotrokinra?

It's a new study medicine being tested to see if it can help reduce the inflammation that causes ulcerative colitis symptoms.

Riceverò sicuramente il nuovo medicinale?

In the adult part of the study, some people will get icotrokinra, and some will get a dummy medicine (placebo). Teenagers will receive icotrokinra.

Per quanto tempo sarò nello studio?

The total study could last about five years, including initial checks, treatment phases, and follow-up.

Devo pagare per partecipare allo studio?

No, the study will cover the costs of the medicine and tests, and you'll get some reimbursement for travel expenses.

Come saperne di più

Jimmy Limdi

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "Study evaluating the efficacy of icotrokinra in ulcerative c…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.